We expect the profitability to improve in coming quarters: Siddharth Mittal, Biocon

Typically, licensing income tends to be lumpy. When we out-license any of our molecule to our customers, we receive the licensing income and we have had an out-licensing deal or transaction with a partner which led to this large income during this quarter